Vaporized cannabis containing standardized percentages of CBD and THC is associated with sustained improvements in patients with multiple sclerosis (MS), according to longitudinal data published in the Journal of Clinical Medicine.
Greek researchers assessed the efficacy of a vaporized cannabis formulation containing 13 percent CBD and 9 percent THC in a cohort of 69 MS patients. Study participants’ symptoms – including bladder dysfunction, muscle spasticity, and disability progression rate – were assessed at baseline, at three months, and six months.
“Significant improvement was observed across all outcome assessments” following patients’ adjunctive use of cannabis, researchers reported.